palivizumab
CHEBI:CHEBI_749782
Drug Classification
-
chemical entityView Class →
CHEBI:24431
Important Medical Information
⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.
- Always consult with a healthcare professional before starting, stopping, or modifying any medication.
- Side effects may vary and this list may not be comprehensive.
- Drug interactions may occur with other medications.
Additional Identifiers
🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.
Additional Attributes
- generic_name
- Palivizumab
- rxcui
- 1657362
- pharm_class
- Fusion Protein Inhibitors [MoA]
- product_type
- BULK INGREDIENT
- listing_expiration_date
- 20251231
- route
- INTRAMUSCULAR
- dosage_form
- LIQUID
- active_ingredient_strength
- 34.6 kg/34.6kg
- marketing_category
- BULK INGREDIENT
- nui
- N0000175615
- pharm_class_cs
- Antibodies, Monoclonal [CS]
- labeler_name
- Swedish Orphan Biovitrum AB (publ)
- marketing_start_date
- 19991209
- package_marketing_start_date
- 24-JUN-16
- product_ndc
- 12714-232
- spl_id
- 18fd64a5-5511-107f-e063-6294a90a9edd
- active_ingredient_name
- PALIVIZUMAB
- package_ndc
- 12714-232-10
- package_description
- 100 mg in 1 VIAL, SINGLE-DOSE (12714-232-10)
- pharm_class_epc
- Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]
- pharm_class_moa
- Fusion Protein Inhibitors [MoA]
- manufacturer_name
- Swedish Orphan Biovitrum AB (publ)
- brand_name
- Synagis
- brand_name_base
- Synagis
- application_number
- BLA103770
- unii
- DQ448MW7KS
- spl_set_id
- 3a0096c7-8139-44cd-bba4-520ab05c2cb2
- upc
- 0366658231013
- 22-rdf-syntax-ns#type
- http://www.w3.org/2002/07/owl#Class